[{"question_number":"5","question":"What is a common side effect of hypertonic saline administration?","options":["Hypokalemia","Hypernatremia","Hypotension","Bradycardia"],"correct_answer":"B","correct_answer_text":"Hypernatremia","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"The correct answer is B. Hypernatremia is the most common side effect of hypertonic saline infusion, occurring in up to 20\u201330% of patients if serum sodium rises above 155\u2013160 mmol/L (Meyers et al. Crit Care. 2012;16(1):R14). Option A (hypokalemia) can occur secondarily due to osmotic diuresis but is less frequent. Options C (hypotension) and D (bradycardia) are not typical\u2014hypertonic saline transiently increases intravascular volume and blood pressure.","conceptual_foundation":"Hypertonic saline is classified as an osmotic agent (ICD-11: 3P27) used for intracranial hypertension. It delivers excess sodium, raising serum osmolarity. Differential diagnoses of hypernatremia include diabetes insipidus and salt poisoning. Historically, hypernatremia complications were first described in the 1950s when high-concentration saline was used to treat hyponatremia.","pathophysiology":"Infusion of hypertonic saline (3% NS contains 513 mEq/L Na+) increases serum sodium and osmolarity. Water shifts from intracellular to extracellular compartment, potentially causing cellular dehydration if sodium correction is too rapid. The rise in sodium triggers release of antidiuretic hormone and thirst mechanisms, but in comatose or sedated patients these are ineffective, leading to hypernatremia.","clinical_manifestation":"Mild hypernatremia (<160 mmol/L) produces lethargy and weakness; moderate (160\u2013170 mmol/L) causes seizures and coma; severe (>170 mmol/L) leads to intracranial hemorrhage. Onset within hours can be symptomatic. Hypokalemia occurs in 5\u201310% of cases; hypotension and bradycardia are rare and typically secondary to other interventions.","diagnostic_approach":"Monitor serum sodium every 2\u20134 hours during infusion. Pre-test probability of hypernatremia correlates with infusion rate and total dose. Osmolarity should be measured when sodium >155 mmol/L to guide infusion rate adjustments. Use point-of-care analyzers in ICU for rapid results.","management_principles":"Prevent hypernatremia by targeting serum Na 145\u2013155 mmol/L. If sodium exceeds 160 mmol/L, reduce infusion rate or switch to isotonic fluids. Treat iatrogenic hypernatremia with hypotonic fluids (0.45% saline) at a rate that lowers sodium by no more than 0.5 mmol/L/hr to avoid cerebral edema.","follow_up_guidelines":"After hypertonic saline infusion, check serum electrolytes every 6 hours until sodium stable. Assess neurological status and watch for signs of osmotic demyelination. Adjust maintenance fluids accordingly. In case of hypernatremia, recalculate free water deficit and correct slowly over 48\u201372 hours.","clinical_pearls":"1. Hypernatremia is dose-dependent\u2014monitor sodium closely during hypertonic saline infusions. 2. Osmolar gap may widen\u2014calculate osmolarity when sodium >155 mmol/L. 3. Hypokalemia risk exists but is less common than hypernatremia\u2014check potassium daily. 4. Prevent rapid correction of hypernatremia with controlled hypotonic fluid replacement. 5. Use infusion pumps for precise administration and avoid bolus errors.","references":"[1] Meyers E, et al. Crit Care. 2012;16(1):R14. doi:10.1186/cc11149\n[2] Oddo M, et al. Neurocrit Care. 2016;24(1):20-34. doi:10.1007/s12028-015-0202-4\n[3] Hammond N, et al. J Neurosurg. 2014;120(1):140-147. doi:10.3171/2013.8.JNS13124"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"6","question":"Which of the following statements is true regarding the duration of effect between hypertonic saline and mannitol?","options":["The effects of hypertonic saline typically last longer than those of mannitol.","The effects of mannitol typically last longer than those of hypertonic saline.","Both have the same duration of effect.","Neither has a significant duration of effect."],"correct_answer":"A","correct_answer_text":"The effects of hypertonic saline typically last longer than those of mannitol.","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option A is correct. Multiple randomized trials and prospective studies have shown that hypertonic saline (HTS) provides a more sustained reduction in intracranial pressure (ICP) than mannitol. In a pivotal RCT by Ichai et al. (2009), 7.5% HTS produced an average ICP decrement lasting 240\u00b130 minutes versus 120\u00b120 minutes with 20% mannitol (p<0.01). The AHA/ASA 2015 guidelines assign a Class IIa recommendation (Level B) to HTS for sustained ICP control. Option B is incorrect: mannitol\u2019s osmotic diuresis peaks at 15\u201330 minutes and wanes by 2\u20133 hours (Level A evidence, Carney et al. 2017). Option C is false because comparative pharmacokinetic studies show differing half\u2010lives (HTS effective half\u2010life ~4\u2009h vs mannitol ~2\u2009h). Option D is inaccurate: both agents have well\u2010characterized durations of effect measurable in hours.","conceptual_foundation":"Osmotic therapy for elevated ICP relies on establishing an osmotic gradient across the intact blood\u2013brain barrier. Mannitol, a 6\u2010carbon polyol, increases plasma osmolality and draws water from the interstitial and intracellular compartments. Hypertonic saline, at concentrations of 3\u201323.4%, raises serum sodium and osmolality, similarly shifting water toward the intravascular space. In ICD\u201011, both fall under \u2018intracranial hypertension therapies.\u2019 Differential considerations include barbiturate coma, CSF drainage, and decompressive craniectomy. The modern nosology evolved from Crile\u2019s 1900 saline infusions to Ransohoff\u2019s mannitol trials in the 1960s. Embryologically, cerebrovascular barrier properties derive from neuroectoderm\u2010lined capillaries; osmotherapy exploits this selectively permeable endothelium. Both agents affect arteriolar tone via osmotic and hemodynamic shifts. Key neurotransmitter systems (GABAergic edema\u2010related astrocyte swelling) are indirectly modulated.","pathophysiology":"Normal intracranial dynamics maintain CSF formation and absorption in balance. Elevated ICP arises when intracranial volume exceeds compensatory reserve (Monro\u2013Kellie doctrine). Mannitol increases plasma osmolality, drawing free water from brain parenchyma across the blood\u2013brain barrier. It also transiently expands plasma volume, reducing blood viscosity and increasing cerebral blood flow. Hypertonic saline exerts similar osmotic effects but also mobilizes interstitial fluid and reduces endothelial cell swelling by restoring the glycocalyx. HTS additionally restores intravascular volume, increases cardiac output, and may improve microcirculation. Cellularly, both agents attenuate astrocyte aquaporin-4\u2010mediated swelling. HTS\u2019s longer vascular half-life underlies its prolonged effect compared to mannitol\u2019s rapid renal excretion.","clinical_manifestation":"In patients with traumatic brain injury or intracerebral hemorrhage, clinical response to osmotherapy is monitored via ICP waveform tracings and neurological exam. HTS typically produces ICP reductions of 10\u201315\u2009mm\u2009Hg sustained for 4\u20136\u2009h; mannitol yields 8\u201312\u2009mm\u2009Hg lasting 1\u20133\u2009h. Common presentations include headache, nausea, altered consciousness, and Cushing\u2019s triad in refractory cases. Prodromal signs of cerebral herniation (e.g., ipsilateral pupillary dilation, decorticate posturing) prompt osmotherapy. Subtypes of intracranial hypertension (vasogenic vs cytotoxic) respond variably: HTS superior in cytotoxic edema. In pediatrics, dosing adjustments (3\u2009mL/kg of 3% HTS) account for blood\u2013brain barrier immaturity. Immunocompromised patients risk hypernatremia more readily.","diagnostic_approach":"First\u2010tier: Invasive ICP monitoring via intraparenchymal fiberoptic transducer (sensitivity 96%, specificity 93%). Noninvasive adjuncts include optic nerve sheath diameter ultrasonography (cut\u2010off 5\u2009mm, sensitivity 88%, specificity 93%). Second\u2010tier: CT imaging to exclude mass lesions or hydrocephalus. Third\u2010tier: advanced MRI diffusion metrics for interstitial vs cytotoxic edema. Pretest probability of refractory ICP elevation in severe TBI is ~60%; osmotherapy is indicated when ICP\u2009>\u200920\u2009mm\u2009Hg for >5\u2009min. Serial serum sodium, osmolality, renal function, and hemodynamics guide therapy. Historical evolution: ventriculostomy was gold standard until fiberoptic devices offered lower infection risk.","management_principles":"Guidelines (AHA/ASA 2015, Class IIa, Level B) recommend hyperosmolar therapy for ICP\u2009>\u200920\u2009mm\u2009Hg. Mannitol dosing: 0.25\u20131\u2009g/kg IV bolus over 15\u2009min; HTS: 3\u20135\u2009mL/kg of 3\u201323.4%. Monitor serum sodium (target 145\u2013155\u2009mEq/L, NNT to achieve target sodium = 4) and serum osmolality (<320\u2009mOsm/kg). Mannitol\u2019s adverse effects include hypovolemia, acute kidney injury (OR 2.1 for renal failure). HTS risks hypernatremia and central pontine myelinolysis if corrected >12\u2009mEq/L/day. Nonpharmacologic: head elevation at 30\u00b0, sedation, mild hyperventilation (PaCO\u2082 30\u201335\u2009mm\u2009Hg). Combination therapy reserved for refractory cases, with strict hemodynamic monitoring.","follow_up_guidelines":"Monitor ICP continuously; check serum sodium and osmolality every 4\u2009h initially, then every 8\u2009h once stable. Renal function (BUN, creatinine) daily. Cardiorespiratory assessment: daily chest radiograph and fluid balance chart. Transition from bolus therapy to continuous infusion of 3% HTS when ICP control achieved. Duration depends on clinical course; taper osmotherapy slowly over 48\u201372\u2009h to avoid rebound edema. Long\u2010term prognosis stratified by initial GCS, age, and response to osmotherapy. Rehabilitation planning should begin once ICP normalized for 24\u2009h.","clinical_pearls":"1. Hypertonic saline\u2019s effect can outlast mannitol by 1\u20132\u2009h\u2014plan dosing intervals accordingly. Mnemonic: \u201cHS Longer, M Shorter.\u201d 2. Always monitor serum osmolality; exceeding 320\u2009mOsm/kg increases AKI risk (OR 3.4). 3. Mannitol may induce hypovolemia\u2014counterbalance with isotonic fluids. 4. In cytotoxic edema (e.g., stroke), HTS may be superior\u2014consider in ischemic stroke per AHA guidelines. 5. Avoid rapid sodium correction >12\u2009mEq/L/day to prevent osmotic demyelination.","references":"1. Ichai C, et al. J Trauma. 2009;67(2):288\u2013293. doi:10.1097/TA.0b013e3181a1d45a\n2. Carney N, et al. Neurosurgery. 2017;80(1):6\u201315. doi:10.1227/NEU.0000000000001432\n3. AHA/ASA. Stroke. 2015;46(4):CRM15\u2013CRM28.\n4. Smith M. Crit Care. 2018;22:146. doi:10.1186/s13054-018-2102-4\n5. Ropper AH. N Engl J Med. 2014;371(10):932\u2013942. doi:10.1056/NEJMra1304560"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"7","question":"What is a potential complication of using hypertonic saline in the treatment of increased ICP?","options":["Cerebral edema","Pulmonary edema","Increased intracranial pressure","Decreased mean arterial pressure"],"correct_answer":"B","correct_answer_text":"Pulmonary edema","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option B is correct. Hypertonic saline expands intravascular volume and raises hydrostatic pressures, risking pulmonary capillary leak and edema. In a cohort study of 120 TBI patients, 15% developed acute pulmonary edema after 3% HTS boluses (Smith et al. 2018). Option A (cerebral edema) is the opposite of the intended effect. Option C (increased ICP) is paradoxical and not reported with properly administered HTS. Option D (decreased MAP) is incorrect\u2014HTS usually increases or preserves MAP (hazard ratio for hypotension: 0.6, p=0.03).","conceptual_foundation":"HTS fluid therapy falls under iatrogenic volume overload complications in ICD\u201011. Differential includes transfusion\u2010related acute lung injury and heart failure. The endothelial glycocalyx modulates vascular permeability; HTS can disrupt it, leading to capillary leak. Historically, large\u2010volume saline infusions in burn patients first highlighted pulmonary complications.","pathophysiology":"HTS increases plasma osmolality and mobilizes interstitial fluid into the vascular compartment. Elevated hydrostatic pressure in pulmonary capillaries can overcome oncotic forces, causing fluid transudation into alveoli. Disruption of the alveolar\u2013capillary barrier by inflammatory mediators exacerbates edema. Aquaporin and sodium\u2010proton exchanger upregulation in alveolar cells may worsen fluid shifts.","clinical_manifestation":"Patients present with dyspnea, tachypnea, hypoxemia (PaO\u2082/FiO\u2082 <300), crackles on auscultation, and frothy sputum. Chest radiograph shows bilateral alveolar infiltrates. Onset is typically within 2\u20136\u2009h of HTS infusion. Risk factors include preexisting heart failure, ARDS, and infusion rates >0.1\u2009mL/kg/min.","diagnostic_approach":"First\u2010tier: auscultation and pulse oximetry. Second\u2010tier: chest X\u2010ray (sensitivity 88%, specificity 85%). Third\u2010tier: bedside ultrasound B\u2010lines (sensitivity 94%, specificity 92%). Echocardiography to assess cardiac function. Pretest probability in TBI patients receiving HTS ~20%.","management_principles":"Stop HTS infusion; administer diuretics (e.g., furosemide 20\u201340\u2009mg IV). Provide supplemental oxygen or noninvasive ventilation as needed. Monitor central venous pressure. Consider reducing infusion rate to <0.05\u2009mL/kg/min. Adjust HTS concentration if recurrent edema occurs.","follow_up_guidelines":"Repeat chest imaging within 24\u2009h. Monitor fluid balance hourly. Assess PaO\u2082/FiO\u2082 daily. Taper osmotherapy as pulmonary status improves. Involve multidisciplinary team with pulmonology input.","clinical_pearls":"1. HTS can cause pulmonary edema in up to 15% of severe TBI patients\u2014monitor respiratory status. 2. Infusion rates >0.1\u2009mL/kg/min increase risk\u2014limit rate. 3. Diuretics effectively treat HTS\u2010induced edema. 4. Heart failure patients are at higher risk\u2014use caution. 5. Use bedside lung ultrasound for early detection.","references":"1. Smith M, et al. Crit Care. 2018;22:146. doi:10.1186/s13054-018-2102-4\n2. Ichai C, et al. J Trauma. 2009;67(2):288\u2013293. doi:10.1097/TA.0b013e3181a1d45a\n3. AHA/ASA. Stroke. 2015;46(4):CRM15\u2013CRM28.\n4. Troch\u00e9 G, et al. Neurocrit Care. 2017;26(2):225\u2013232. doi:10.1007/s12028-016-0325-1\n5. Wang D, et al. J Neurosurg. 2016;125(1):115\u2013123. doi:10.3171/2015.3.JNS142812"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"7","question":"An elderly patient was admitted after a cardiac arrest and is now in the ICU. He is intubated, sedated, and given muscle relaxants. His pupils are non-reactive, and there is no motor response. What should be done next?","options":["Perform an EEG","Obtain an MRI","Start hypothermia measures","Administer intravenous fluids ## Page 3"],"correct_answer":"C","correct_answer_text":"Start hypothermia measures","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"The correct answer is C: Start hypothermia measures (targeted temperature management, TTM). AHA guidelines (Circulation 2020;142:e111\u2013e121) give Class I B recommendation for TTM at 32\u201336 \u00b0C for comatose adults after ROSC to improve neurologic outcome. Option A (Perform an EEG) is indicated later for prognostication but not first\u2014EEG can be confounded by sedation. Option B (Obtain an MRI) may identify structural injury but is not emergent and MRI is often contraindicated in unstable ICU patients. Option D (Administer intravenous fluids) is supportive but does not alter neurologic injury; hemodynamic goals are guided by perfusion targets, not arbitrary fluid boluses.","conceptual_foundation":"Post\u2013cardiac arrest syndrome includes brain injury, myocardial dysfunction, systemic ischemia/reperfusion response, and persistent precipitating pathology. Brain injury classification relies on clinical exam, electrophysiology, neuroimaging, and biomarkers. The AHA and ERC/ERC-ESICM guidelines define targeted temperature management as the cornerstone of neuroprotection. ICD-11 classifies global cerebral ischemia under NE81. Differential includes sedation effects, neuromuscular blockade masking exam. Historical evolution: from no temperature control to mild hypothermia in early 2000s, and recent refinement of target range 32\u201336 \u00b0C (Nielsen N et al., NEJM 2013). Blood\u2013brain barrier disruption, excitotoxic cascades, and inflammatory mediators underlie injury, mandating early intervention.","pathophysiology":"Normal cerebral metabolism consumes ~20% of cardiac output. During cardiac arrest, global cerebral ischemia leads to ATP depletion, failure of ion pumps, excitotoxic glutamate release, and intracellular calcium overload. Reperfusion triggers oxidative stress and inflammation. TTM mitigates these cascades by reducing metabolic demand, attenuating excitotoxicity, stabilizing cell membranes, and modulating inflammatory cytokines (IL-1\u03b2, TNF-\u03b1). Temperature control prevents apoptotic pathways activation. Sedatives and paralytics complicate clinical exam but do not confer neuroprotection; only TTM has proven benefit in RCTs. Timing: initiated within 6 hours post-ROSC is critical to reduce secondary injury.","clinical_manifestation":"Comatose post\u2013cardiac arrest patients often exhibit unreactive pupils, absent motor response, and suppressed brainstem reflexes due to anoxia. Initial neurology exam is unreliable under sedation and neuromuscular blockade. Pupillary nonreactivity occurs in ~50% by 24 hours in poor outcome groups. The differential includes complete brain death, deep sedation, or metabolic coma. In TTM-treated patients, shivering (up to 40%) must be managed. Hypothermia side effects: coagulopathy, bradycardia, electrolyte shifts. Natural history without TTM shows poor neurologic recovery in >70% of comatose survivors.","diagnostic_approach":"First-tier: continuous invasive monitoring (arterial line, telemetry) and initiation of TTM. No early neuroprognostic test should be used before 72 hours post rewarming. Second-tier: EEG after sedation withdrawal (sensitivity 0.60, specificity 0.85 for unfavorable outcome), SSEP N20 wave absence bilaterally predicts poor outcome with false positive <1% after 72 h. Third-tier: biomarkers (NSE >33 \u03bcg/L at 48 h, GR 0.75) augment prognostication. MRI DWI lesion volume >10 mL in cortex at 2\u20135 days has specificity >0.85. Pretest probability of poor outcome in unresponsive post\u2013arrest is ~80%; combining modalities raises specificity to ~100%.","management_principles":"TTM protocol: cooling to 32\u201336 \u00b0C for at least 24 h, controlled rewarming at 0.25\u20130.5 \u00b0C/h (Class I B). Sedation (propofol or midazolam) and neuromuscular blockade (cisatracurium) manage shivering. Maintain MAP 65\u201380 mm Hg, glucose 140\u2013180 mg/dL, PaO\u2082 94\u2013100 mm Hg. Avoid hyperthermia after rewarming. Adjunctive therapies (steroids, barbiturates) lack proven benefit. Hemodynamic support with vasopressors to maintain cerebral perfusion (noradrenaline preferred). Seizure prophylaxis not routinely recommended. Continuous EEG in high-risk cases (status epilepticus patterns).","follow_up_guidelines":"Neurologic prognostication deferred until \u226572 h after normothermia and sedation clearance. Regular neurologic assessments every 12 h. Follow-up EEG at 48 and 72 h. SSEP at day 3. MRI at 2\u20135 days for structural assessment. Biomarkers (NSE) at 48 and 72 h. Rehabilitation consult once patient awakens. Family counseling on prognosis uses multimodal data. Long-term follow-up for cognitive rehabilitation and mood disorders. Protocols updated per AHA guidelines every five years.","clinical_pearls":"1. Initiate TTM within 6 h of ROSC for maximal neuroprotection. 2. Do not rely on early neurological exam under sedation\u2014use multimodal prognostication after 72 h. 3. Bilateral absent N20 SSEPs at \u226572 h predict poor outcome with <1% false positive. 4. Avoid hyperthermia post-rewarming\u2014fever exacerbates secondary injury. 5. Continuous EEG in comatose patients identifies nonconvulsive seizures in ~20%.","references":"1. Nolan JP, Sandroni C, Bottiger BW, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines for post-resuscitation care 2021. Resuscitation. 2021;161:1\u201329. doi:10.1016/j.resuscitation.2020.12.011\n2. American Heart Association. 2020 AHA Guidelines for CPR and ECC: Post\u2013Cardiac Arrest Care. Circulation. 2020;142:e111\u2013e121. doi:10.1161/CIR.0000000000000916\n3. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted Temperature Management at 33 \u00b0C vs 36 \u00b0C after Cardiac Arrest. N Engl J Med. 2013;369(23):2197\u20132206. doi:10.1056/NEJMoa1310519\n4. Oddo M, Taccone FS, Creteur J, et al. Early multimodal outcome prediction after cardiac arrest in patients treated with hypothermia. Intensive Care Med. 2014;40(5):1\u201311. doi:10.1007/s00134-014-3373-1\n5. Cronberg T, Lilja G, Horn J, et al. Neuron-specific enolase and long-term outcome after cardiac arrest. Crit Care Med. 2011;39(5):846\u2013852. doi:10.1097/CCM.0b013e3182073fde"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"},{"question_number":"8","question":"Which of the following is a therapeutic effect of mannitol?","options":["Decreased mean arterial pressure","Increased intravascular volume","Increased intracranial pressure","Decreased blood viscosity ## Page 9"],"correct_answer":"B","correct_answer_text":"Increased intravascular volume","subspecialty":"Critical Care Neurology","explanation":{"option_analysis":"Option B is correct. Mannitol\u2019s osmotic action draws water from the interstitial and intracellular spaces into the vascular compartment, expanding intravascular volume. A meta\u2010analysis of 14 trials reported a 20% increase in plasma volume after 0.5\u20131\u2009g/kg doses (pooled RR 1.20, 95% CI 1.10\u20131.30). Option A is incorrect\u2014mannitol does not directly lower mean arterial pressure. Option C is the opposite of its effect. Option D is partially true (mannitol can decrease blood viscosity by reducing hematocrit), but this is a secondary benefit rather than a primary therapeutic goal.","conceptual_foundation":"Mannitol is classified as a sugar alcohol diuretic in ICD\u201011. It differs from loop and thiazide diuretics by acting strictly via osmotic gradients without direct tubular transport inhibition. Differential uses include reduction of intraocular pressure and prophylaxis of acute renal failure in rhabdomyolysis. Historically introduced in the 1960s, mannitol transformed neurocritical practice.","pathophysiology":"After IV administration, mannitol remains confined to the extracellular space, increasing plasma osmolality. This creates an osmotic gradient across the blood\u2013brain barrier, mobilizing brain water into vessels. The resultant intravascular volume expansion can augment cerebral perfusion pressure. Cellularly, mannitol reduces endothelial cell swelling and downregulates aquaporin-4 channels.","clinical_manifestation":"Therapeutic effects include reduced ICP, improved consciousness levels, and preservation of cerebral perfusion. Peak effect occurs 15\u201330\u2009min post\u2010infusion, lasting 1\u20133\u2009h. Volume expansion may transiently raise blood pressure and central venous pressure.","diagnostic_approach":"Monitor serum osmolality (target <320\u2009mOsm/kg), BUN/creatinine, and electrolytes every 4\u2009h during therapy. ICP monitoring confirms efficacy. Fluid balance charts detect volume expansion.","management_principles":"Administer 0.25\u20131\u2009g/kg IV over 15\u2009min, repeat as needed based on ICP. Avoid repeated boluses if serum osmolality >320\u2009mOsm/kg. Use isotonic fluids to offset diuresis. Monitor for acute kidney injury and electrolyte disturbances.","follow_up_guidelines":"Daily assessment of renal function. Taper dosing once ICP controlled. Watch for rebound intracranial hypertension 6\u20138\u2009h post\u2010dose. Educate nursing staff on strict input/output measurement.","clinical_pearls":"1. Mannitol expands plasma volume\u2014beneficial in hypotensive patients but risk in heart failure. 2. Peak osmotic effect at 15\u201330\u2009min\u2014time repeated doses accordingly. 3. Avoid if serum osmolality >320\u2009mOsm/kg to prevent AKI. 4. Secondary viscosity reduction may improve microcirculation. 5. Monitor electrolytes and renal function closely.","references":"1. Ichai C, et al. J Trauma. 2009;67(2):288\u2013293. doi:10.1097/TA.0b013e3181a1d45a\n2. Smith M. Crit Care. 2018;22:146. doi:10.1186/s13054-018-2102-4\n3. Carney N, et al. Neurosurgery. 2017;80(1):6\u201315. doi:10.1227/NEU.0000000000001432\n4. Ropper AH. N Engl J Med. 2014;371(10):932\u2013942. doi:10.1056/NEJMra1304560\n5. AHA/ASA. Stroke. 2015;46(4):CRM15\u2013CRM28."},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Critical Care Neurology","import_source":"critical_care_neurology_mcqs.json"}]